Research Article
A Retrospective Longitudinal Cohort Study of Antihypertensive Drug Use and New-Onset Diabetes in Taiwanese Patients
Table 1
Baseline characteristics of all patients.
| | | NOD | Non-NOD | Total | value | | | () | () | () |
| | Age (year-old) | 59.8 ± 11.4 | 56.4 ± 13.6 | 56.8 ± 13.4 | 0.003 | | Male (%) | 50 (42) | 397 (45) | 447 (45) | 0.537 | | Current smoking (%) | 19 (16) | 122 (14) | 141 (14) | 0.496 | | Familial history of DM (%) | 18 (15) | 105 (12) | 123 (12) | 0.338 | | BMI ≥ 27 (%) | 43 (36) | 202 (23) | 245 (24) | 0.002 | | Systolic blood pressure (mm Hg) | 148.7 ± 10.2 | 149.0 ± 9.8 | 149.0 ± 9.9 | 0.824 | | Diastolic blood pressure (mm Hg) | 77.8 ± 6.2 | 77.8 ± 6.0 | 77.8 ± 6.0 | 0.892 | | TC (mg/dL) | 227 ± 28 | 219 ± 35 | 220 ± 34 | 0.005 | | TG (mg/dL) | 152 ± 52 | 130 ± 45 | 133 ± 51 | <0.001 | | LDL-C (mg/dL) | 138 ± 30 | 131 ± 36 | 132 ± 35 | 0.019 | | HDL-C (mg/dL) | 58 ± 13 | 60 ± 17 | 60 ± 16 | 0.114 | | FBG (mg/dL) | 101 ± 10 | 85 ± 12 | 87 ± 12 | <0.001 | | Serum creatinine (mg/dL) | 1.16 ± 0.32 | 1.13 ± 0.33 | 1.13 ± 0.33 | 0.351 | | Number of prescription (%) | | | | 0.040 | | 1 | 29 (24) | 205 (23) | 234 (23) | | | 2 | 42 (35) | 308 (35) | 350 (35) | | | 3 | 40 (33) | 302 (34) | 342 (34) | | | 4 | 8 (7) | 56 (6) | 64 (6) | | | 5 | 1 (1) | 10 (1) | 11 (1) | | | Drug class | | | | | | Thiazide diuretics (%) | 38 (32) | 215 (24) | 253 (25) | 0.054 | | Beta-blockers (%) | 76 (63) | 518 (59) | 594 (59) | 0.399 | | DHP CCBs (%) | 68 (57) | 474 (54) | 542 (54) | 0.528 | | Non-DHP CCBs (%) | 13 (11) | 63 (7) | 76 (8) | 0.102 | | Alpha-blockers (%) | 15 (13) | 148 (17) | 163 (16) | 0.233 | | ACE inhibitors (%) | 17 (14) | 132 (15) | 149 (14) | 0.771 | | ARBs (%) | 37 (31) | 289 (33) | 326 (33) | 0.634 | | Vasodilators (%) | 16 (13) | 107 (12) | 123 (12) | 0.591 |
|
|
*
value between NOD and non-NOD.
DM: diabetes mellitus. BMI: body mass index. TC: total cholesterol. TG: triglyceride. FBG: fasting blood glucose. DHP-CCB: dihydropyridine calcium channel blockers. Non-DHP CCB: Nondihydropyridine calcium channel blockers. ACE: angiotensin converting enzyme. ARB: angiotensin receptor blocker.
|
